The first results of Pfizer are based on clinical trials for just over 1,200 adults who have contracted COVID-19 and a risk of developing a serious case of the disease.
Le Monde with AFP
This is the second treatment of this type to demonstrate positive results. After the tablet developed by Merck, which was authorized Thursday in the United Kingdom, Pfizer announced on Friday, November 5, that its pill against CVIV-19 was effective at 89% to prevent the risk of hospitalization or death, according to the First results of clinical trials. The company has stated that it intends to provide these results “as soon as possible” to the US Medicines Agency (FDA) for an application for authorization.
Antivirals act by reducing the ability of a virus to replicate, thus braking the disease. Easy to administer, these treatments represent a complement to the vaccines to protect from COVID-19. The treatment of Pfizer will be marketed as Paxlovid.
The first results of Pfizer are based on clinical trials for just over 1,200 adults, which has contracted CVIV-19 and at risk of developing a serious case of the disease. In the few days after the appearance of the symptoms, some received the pfizer pill, and others a placebo.
“overwhelming efficiency”
“The interim analysis showed a reduction of 89% of the risk of hospitalization related to the CVIV-19 and death of any cause, compared to a placebo in patients treated within three days of the following Appearance of symptoms, “said Pfizer in a statement.
The test will include 3,000 people, but the recruitments were stopped “in the face of the overwhelming efficiency” of treatment in the first results, said Pfizer.
“Today’s announcement really changes the situation in our global efforts to stop the ravages caused by this pandemic”, welcomed the boss of Pfizer, Albert Bourla, cited in the press release. “These data suggest that our candidate antiviral treatment, if approved by the regulatory authorities, has the potential to save patient lives, reduce the severity of CVIV-19 infections, and avoid up to nine on ten hospitalizations,” has he added.